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Summary
Gout is a common condition and its management is subop-
timal. A number of guidelines on the management of gout
have been published in the last decade by professional soci-
eties with the aim of informing the physician of the recom-
mended therapeutic strategies and the treatment options.
We have tried to synthesize the current recommendations
and to highlight some challenges that still need to be re-
solved in clinical practice in Switzerland.
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Introduction
Gout is a urate crystal deposition disease due to underlying
hyperuricaemia, and both are common conditions that have
seen a marked increase in both incidence and prevalence in
the last 30 years. No Swiss data are available to document
its extent in Switzerland, but based on data from the UK
[1] and Germany [2], it would be safe to assume that gout
affects between 1% and 2% of the adult population, and is
probably the most frequent cause of inflammatory arthritis
in adult males [3]. A temporal trend of increasing preval-
ence of gout over the last 15 years was observed in the UK
data, in particular affecting the elderly, and this is in agree-
ment with our clinical experience in Lausanne.
The treatment of gout rests on two primary objectives – the
relief of pain of the acute gouty attack and the reduction
of serum urate to a level that prevents further urate crystal
deposition. In most cases, the causes of hyperuricaemia
and gout are unknown and long-term treatment with urate
lowering therapy (ULT) aims to bring the serum urate level
to below a target level of 360 μmol/l, a threshold that fa-
vours crystal dissolution. Dietary modifications and avoid-
ance of drugs that provoke hyperuricaemia are indispens-
able adjuncts to pharmacological therapy in patients with
established gout, but are generally insufficient by them-
selves [4]. No controlled trials of dietary therapy in gout
have been performed to date.
Our current challenges in the management of gout are:
the limited number of effective medical therapies that are
available to our patients, particularly in Switzerland; the
generally high level of attrition of patients on long term
ULT; and the rational prescription of ULT in patients who
often have significant cardiovascular and renal comorbidit-
ies. In fact, the presence of comorbidities is one of the ma-
jor barriers to effective treatment of both acute attacks of
gout and hyperuricaemia.
Recent advances in the understanding of the patho-
physiology of gout [5, 6] and the development of new
drugs have led to renewed interest in this old disease. It
is widely recognised that gout is poorly treated in general,
and there are multiple obstacles to care, in particular in
adherence to therapy [7, 8]. One way to overcome some
of these barriers is the development of guidelines to help
the clinician to manage gout more effectively [9, 10]. In
Switzerland, no local guidelines exist and clinicians fre-
quently refer to international guidelines from other coun-
tries. In this review, we have analysed and compared the
current international guidelines for the management of gout
and identified points that are common to the published
guidelines, as well as differences. We hope this information
will be useful to Swiss clinicians and inform their choice of
therapy.
Methods
Recently published guidelines on the management of gout
and hyperuricaemia formed the starting point of our ana-
lyses. These include the guidelines published by European
League against Rheumatism [9], the American College of
Rheumatology (ACR) [10, 11], the British Society of
Rheumatology [12] and the Japanese Society of Gout and
Nucleic Acid Metabolism [13], as well as an international
expert group called the 3e initiative [14]. All the published
guidelines used an evidence-based medicine approach to
produce their recommendations. In the event of differences
in the guidelines’ recommendations, we performed a lit-
erature review of publications that are cited in PUBMED
from 1999 to 2015, and analysed the data according to
the criteria of the Centre for Evidence-based Medicine (ht-
tp://www.cebm.net). We have listed the different treat-
ments used, their usual dose and dose adaptation when in-
dicated (e.g., in the presence of renal impairment).
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Who to treat
All guidelines recommend initiating ULT in cases of estab-
lished gout (i.e. presence of tophi or evidence of multiple
joint involvement and recurrent attacks, joint damage with
typical erosions). The diagnosis of gout can be based on
clinical criteria, but the gold standard remains the identi-
fication of crystals in the joint fluid by microscopy. Recent
studies have identified clinical features that may help the
clinician to reach a diagnosis in the absence of microscopy,
but their sensitivity and specificity are inferior to crystal
identification [15, 16].
There is no consensus on whether pharmacotherapy should
be started after the first attack of gout in all patients, but
if a patient has had more than two attacks, it is usually re-
commended. In patients who have had only one attack, but
who also have coexisting medical problems such as chronic
kidney disease (CKD) >stage 2 or a history of nephrolith-
iasis, initiation of ULT is generally recommended. All the
guidelines, the Japanese guideline being the exception, cur-
rently do not recommend treatment of asymptomatic hy-
peruricaemia. In Japan, ULT is recommended in asympto-
matic hyperuricaemia (serum level >8 mg/dl [480 μmol/
l]) if coexisting conditions such as renal impairment, neph-
rolithiasis, hypertension, ischaemic heart disease, diabetes
or the metabolic syndrome are present. There is evidence
from clinical trials that ULT (in particular with allopurin-
ol) may have beneficial effects in patients with heart fail-
ure and hypertension, and not necessarily all have hyperur-
icaemia; but these studies are in the main short-term and of
small sample size [17, 18].
Treatment of acute gout and flare
prophylaxis
General principles
All recommendations agree on the importance of prompt
pharmacological treatment of an acute gout attack, and
treatment should be started upon the first signs and symp-
toms of an acute attack (ideally within the first 24 hours).
Nonpharmacological treatments, such as topical ice-packs,
may be useful adjuncts but by themselves are usually insuf-
ficient to treat an acute attack.
Treatment of an acute attack
The most commonly used drugs are oral nonsteroidal anti-
inflammatory drugs (NSAIDs), oral colchicine and cor-
ticosteroids. There is good evidence of efficacy for all three
when used as monotherapy [19–22]. Table 1 summarises
the agents currently used to treat an acute attack.
Nonsteroidal anti-inflammatory drugs
As mentioned above, NSAIDs are considered the first-line
treatment for management of an acute gout attack. All re-
commendations agree that fast-acting oral NSAIDs at max-
imum doses should be prescribed as soon as an acute attack
occurs, and should be continued until complete resolution
of the attack. Six NSAIDs (naproxen, indomethacin, tenox-
icam, celecoxib, etoricoxib and etodolac) have been stud-
ied in a randomised controlled trial setting for the treatment
of gout [19, 20, 22–25]. Only one of them (tenoxicam) was
compared with placebo [26].
The recommended treatment dosages are:
1. Naproxen 500 mg twice daily.
2. Indomethacin 50 mg three times daily
3 Tenoxicam 40 mg once daily
5. Etoricoxib 120 mg once daily
NSAIDs should not be used when known contraindications
(allergies, bleeding disorders, CKD, etc.) are present.
Colchicine
Colchicine is an historical treatment for gout, but its use
has had a poor reputation in Switzerland because of side
effects, some of which were fatal. This was probably a
result of the use of higher doses of colchicine in older
recommendations. Current evidence shows that lower start-
ing doses are just as effective and have fewer side effects,
the most common being diarrhoea. For colchicine, a start-
ing dose of 1 or 1.2 mg is recommended (dosing depends
on the formulation of colchine, which is different in the
USA vs EU countries), followed by 0.5 or 0.6 mg in the
next 2–3 hours on the first day, and then a daily dose of
up to 1.5 mg daily until complete resolution of symptoms
[10]. The pharmacokinetics of colchicine in the context of
renal impairment have not been extensively studied, but
the drug is eliminated primarily by the kidney, so dosage
should be reduced in patients with CKD, and patients with
severe CKD should be monitored closely in case of side ef-
fects [27].
Corticosteroids
Corticosteroids are often used when an NSAID or col-
chicine are contraindicated, such as in patients who have
severe renal impairment, but have also been compared dir-
ectly with indomethacin in a randomised controlled trial
and found to be equally effective and less likely to provoke
gastrointestinal side effects [22]. The recommended oral
dose, according to the ACR guidelines, is around 0.5 mg/kg
per day. This dose can either be maintained for 5–10 days
or given for 2–5 days, followed by gradual tapering over
7–10 days.
Alternative methods of administration of corticosteroids in-
clude intramuscular injection or intra-articular injection,
which are also effective and are recommended in the
guidelines. In the case of intramuscular corticosteroids, tri-
amcinolone acetate 40–60 mg has been shown to be effect-
ive [28] and in clinical practice methylprednisolone 40–80
mg is often used, but has not been studied specifically. The
dose of intra-articular corticosteroids depends on the size
of the joint, but typically a knee or shoulder joint can be in-
jected with 40 mg of methylprednisone [29]. This approach
is particularly suitable for a patient presenting with one or
two affected joints, but is obviously not feasible in patients
with gouty polyarthritis.
Interleukin-1 inhibitors
Interleukin-1beta (IL-1β) has been shown to be a key cy-
tokine mediating gouty inflammation and IL-1 inhibitors
have been shown to be effective in randomised controlled
trials and in case series. The ACR guidelines include IL-1
inhibitors as “off-label therapy”, which can be considered
in patients who do not respond adequately to conventional
Review article: Biomedical intelligence Swiss Med Wkly. 2016;146:w14341
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 7
therapy or who have contraindications to these drugs
(NSAIDs, colchicine and steroids). Two IL-1 inhibitors are
currently licensed for clinical use (anakinra and canakin-
umab). Neither is registered for the treatment of gout in
Switzerland, although canakinumab has obtained approv-
al from European Medicines Agency for the treatment of
gout. The use of anakinra is typically of short duration; it
is given at a dose of 100 mg subcutaneously daily for three
consecutive days. In the case of canakinumab, a 150-mg
dose subcutaneously has been found to be rapidly effective
in randomised controlled trials of acute gout, and also com-
pared favourably to triamcinolone in terms of pain relief
and protection from subsequent flares [30]. Both agents
may help the patient who has persistent gouty arthritis and
who is refractory to standard treatments, but their safety
profiles and risk/benefit ratios require further assessment
[31].
Pharmacological prophylaxis of acute attacks
Acute flares are frequently precipitated by the introduction
of ULT. The flare rate is highest during the first 3 months
of starting ULT, but the increase can persist for up to 6
months, hence the recommendation to give prophylaxis
against gout flares for up to 6 months. In principle, the
same medications used in treating acute attacks are given,
and treatment should be tailored to the individual patient
according to medical history and comedications. It is prob-
ably not necessary to start prophylaxis before ULT, but
there is some variation in clinical practice based on experi-
ence.
Colchicine
Colchicine is probably the drug most frequently recom-
mended for prophylaxis, on the basis of data from numer-
ous randomised controlled trials of ULT. The daily dose
is 0.5 to 1 mg daily and the dose should be adjusted in
the presence of renal impairment. Recent randomised con-
trolled trials of ULTs have included colchicine as prophy-
laxis on starting therapy. A significant flare rate was ob-
served when prophylaxis was only given for 2 months,
hence the recommendation for a 6-month duration of pro-
phylaxis [32]. In patients with non-tophaceous gout, the
ACR guidelines have also recommended prophylaxis to be
maintained for 3 months after the patient has achieved his
target urate level. Other guidelines found reasonable evid-
ence to support the use of low dose colchicine for prophy-
laxis, but without suggesting a dosing regimen.
Nonsteroidal anti-inflammatory drugs
There is a small body of evidence for the use of NSAIDs in
prophylaxis. Guidelines generally suggest use of moderate-
to-low doses of an NSAID (such as naproxen 250 mg
twice daily). The effective doses of other NSAIDs have
not been reported in the literature, but it is likely that they
are equally effective. Obviously, care should be taken when
prescribing NSAIDs in the context of known contraindica-
tions (such as CKD or bleeding disorders).
Treatment of hyperuricaemia and
established gout with urate lowering
therapies
Reducing the serum urate level in order to prevent crystal
deposition and accumulation is the cornerstone of our
therapeutic approach in gout. The patient population that
requires treatment has already been discussed, but it is rel-
evant to point out that some clinicians feel that even pa-
tients who have had only one proven attack of gout could
benefit from ULT. The aim of ULT is to bring the urate
level to less than 360 μmol/l (6 mg/dl), which is generally
accepted to be the solubility threshold of urate in blood.
All guidelines recognise that this is the minimum target we
should aim for in our patients, and in some clinical situ-
ations, such as tophaceous gout, the target should be even
Table 1: Pharmacological approaches to the treatment of acute gout.
Usual daily dose Duration of treatment In cases of renal failure Supporting literature
NSAIDS Naproxen 500 mg b.d.
Indomethacin 50 mg b.d.
Celecoxib 800 mg once, then
400 mg on day 1, then 400 mg
b.d.
Tenoxicam 40 mg q.d.
Etoricoxib 120 mg q.d.
Until attack completely resolves Not recommended Janssens et al. [19]
Schumacher et al. [20]
Schumacher et al. [23]
Garcia de la Torre et al. [24]
Schumacher et al. [20]
Colchicine 0.5–1.5 mg per day. 2 or 3 days after resolution of
clinical signs
Dose reduction in patients with
severe CKD [23]
Ahern et al. [21]
Oral glucocorticoids 0.5 mg/kg per day.
Prednisone 30 mg day one, then
taper over 7–10 days.
Up to 10 days, followed by
discontinuation
Not contraindicated Man et al. [22]
Intra-articular glucocorticoids Triamcinolone:
Large joint 40 mg.
Medium joint 30 mg.
Small joint 10 mg (1).
Not contraindicated Fernandez et al. [29]
Parenteral glucocorticoids IM: Triamcinolone 60 mg (2),
followed by oral prednisone.
IV: Methylprednisone 20 mg.
Stepwise dose reduction by half
when improvement begins.
IM: repeat at 48 h if symptoms
persist.
IV: 5 days.
Not contraindicated IM: ACR panel recommendation.
IV: Treatment of acute gout.
Becker et al. Up-to-date article
Anti IL-1 Anakinra: 100 mg SC
Canakinumab: 150 mg
Anakinra: For 3 days. Not known Dumusc et al. [31]
Schlesinger et al. [30]
ACR = American College of Rheumatology; b.d. = twice daily; CKD = chronic kidney disease; IL-1 = interleukin-1; IM = intramuscularly; IV = intravenously; NSAIDS =
nonsteroidal anti-inflammatory drugs; q.d. = once daily; SC = subcutaneously
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lower (e.g., below 300 μmol/l). As mentioned previously,
there are multiple lines of evidence that hyperuricaemia
may contribute to a deterioration of renal and cardiovascu-
lar function, but all current guidelines, except the Japanese
guideline, do not recommended treatment of asymptomat-
ic hyperuricaemia as there is a lack of data from long-term,
large scale research trials in this sector.
The first step in the management of all cases of gout is
to ensure that the patient is informed of nonpharmacolo-
gical approaches (diet and lifestyle recommendations), the
avoidance of substances (including drugs) that elevate ser-
um urate and the importance of long-term adherence to
treatment of the condition. Diuretics (thiazide and loop) are
commonly prescribed drugs for heart failure that contribute
to hyperuricaemia, and if possible their dose should be re-
duced. These general measures are summarised in table 2.
In most cases, a nonpharmacological approach is insuffi-
cient to halt the evolution of gouty arthritis or to reduce the
serum urate to the target level. ULT with either a xanthine
oxidase inhibitor or with a uricosuric agent is effective in
lowering serum urate, although there is considerable indi-
vidual variation in the response to a specific drug as well
as in tolerability of medication. In general, monotherapy is
the approach of choice, although combining a xanthine ox-
idase inhibitor with a uricosuric has also been successful.
The treatments and their clinical applications are summar-
ised in table 3.
Xanthine oxidase inhibitors
All guidelines recommend starting ULT with a xanthine
oxidase inhibitor. The most commonly prescribed is allop-
urinol, as it is widely available. The dose of allopurinol
should be increased progressively, starting at a dose of 100
mg/day and increased every 2–5 weeks by 100 mg/day in
order to achieve the target serum urate level [1, 2]. Many
physicians wrongly believe that the maximum daily dose is
300 mg, and do not escalate allopurinol above this level.
However, less than 50% of patients achieve a target urate
level of 360 μmol/l with 300 mg daily [32]. The maximum
recommended dose is 900 mg/day in patients without ren-
al impairment. The concern with higher doses, the potential
association with severe side effects (allopurinol hypersens-
itivity syndrome, Stevens-Johnson syndrome), has led to
adoption of guidelines recommending dose reduction in pa-
tients with CKD [33]. Some recent data showed that care-
ful and gradual dose increases above 300 mg are not asso-
ciated with major side effects [34] and the ACR guidelines
support this approach, as long as there is close clinical sur-
veillance. The ACR guidelines also recommend testing for
the presence of HLA-B*5801 in patients who may have a
higher risk of developing allopurinol hypersensitivity syn-
drome (e.g., Koreans, Han Chinese and Thai) as in these
Table 2: General measures in the management of hyperuricaemia
(based on American College of Rheumatology recommendations
[11]).
Drugs Avoid drugs or substitute drugs that cause
hyperuricaemia, e.g. thiazides, calcineurin
inhibitors
Dietary
modifications
Avoid high purine content foods, sugary (high
fructose content) drinks
Alcohol
consumption
Limit consumption of alcohol, in particular beer and
spirits
General health
measures
Increase in physical activity, weight reduction
Table 3: Summary of commonly used urate lowering therapies and their usage.
Initiation Management
therapy
Usual dosage Maximum
dosage
In renal failure Haemodialysis Contraindications
Allopurinol
(Zyloric®)
100 mg/day Increase by 100
mg/day every 2–5
weeks.
300 mg/day 900 mg/day Starting dosage: 50 mg/
day (in stage 4 or worse
CKD). Dose can be
raised above 300 mg/day
with adequate patient
education + monitoring.
100 mg alternate days
given after dialysis. With
daily dialysis: an
additional 50% of the
dose may be required
postdialysis.
Hypersensitivity syndrome.
Test for HLA-B*5801 in
patients at higher risk of
allopurinol hypersensitivity
syndrome
Concomitant use of
azathioprine or
mercaptopurine
Febuxostat
(Adenuric®)
40 mg/day Increase to 80 mg/
day after 2 weeks
if the target is not
reached.
80 mg/day 120 mg/day No adjustment. More
effective at 80 mg/day
Not been studied Concomitant use of
azathioprine or
mercaptopurine
Benzbromarone
(Desuric®)
100 mg/day Increase by 50
mg/day
increments until
the serum urate
level is in the
target
100 mg/day 200 mg/day No significant effect (in
combination) with CrCl
<30 ml/min.
Probably not effective Hepatic disease, past
history of nephrolithiasis
Probenecid
(Santuril®)
250 mg 2×/day
for 1 week
then 500 mg
2×/day
Increase dosage
by 500 mg every 4
weeks
500 mg 2×/day 1000 mg 2×/
day
Not effective with a CrCl
<30 ml/min. Not
recommended first-line
therapy with CrCl <50 ml/
min.
No recommendations Past history of
nephrolithiasis
Pegloticase 8 mg 1×/
2 weeks
Always the same
dosage. No
consensus on the
appropriate
duration of
therapy.
8 mg 1×/
2 weeks
8 mg 1×/
2 weeks
No adjustment. No recommendations Glucose-6-phosphate
dehydrogenase deficiency
CKD = chronic kidney disease; CrCl = creatinine clearance
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populations the presence of HLA-B*5801 significantly in-
creased the odds ratio of developing a severe reaction [35].
Febuxostat is a newer xanthine oxidase inhibitor that is, un-
fortunately, not yet available in Switzerland. Many stud-
ies have compared its efficacy with that of allopurinol in
lowering urate to the target of <360 μmol/l. Febuxostat 40
mg/day is equivalent in efficacy to allopurinol 300 mg/
day in lowering urate levels and it is more normally pre-
scribed at a dose of 80–120 mg/day [36]. An advantage
of febuxostat is that no dose adjustment is necessary with
CKD, and it is an alternative to allopurinol in patients
with CKD and patients who are hypersensitive to or show
intolerance of allopurinol. Febuxostat is recommended as
first-line therapy together with allopurinol in the ACR
guidelines [11].
Uricosurics
As second-line therapy, all guidelines recommend a uricos-
uric. This treatment increases the renal excretion of urate
and is, therefore, not recommended for patients with a his-
tory of renal lithiasis. In Switzerland, probenecid (Santur-
il®) is the main choice; benzbromarone (Desuric®) is a
more effective uricosuric, but it is available only in hos-
pitals and is reserved for patients who did not tolerate al-
lopurinol. Probenecid can be introduced as monotherapy
or in combination with a xanthine oxidase inhibitor. A
study on the efficacy and tolerability of probenecid demon-
strated that the target serum urate level is achieved more
frequently when it is combined with allopurinol than when
it is given as monotherapy [37]. Benzbromarone is more
potent that probenecid in reducing serum urate [38] and
has been studied as monotherapy or in combination with a
xanthine oxidase inhibitor. The usual daily dose is between
100 mg and 200 mg. Because of reports of acute liver in-
jury, it is important to check liver function before and dur-
ing treatment [39].
Pegloticase
Pegloticase is a pegylated form of uricase that is available
in the USA (Krystexxa®), but not in Switzerland, for the
treatment of gout that has not responded to other standard
therapies. It is an intravenous treatment given once every
2 weeks and has been shown to be extremely effective,
compared with placebo, in achieving the target serum urate
level [36]. The treatment is associated with potential aller-
gic reactions to the drug. There is no consensus on the ap-
propriate duration of therapy [11].
Urate lowering therapy and chronic kidney disease
Treating patients with renal impairment is a common scen-
ario in gout and requires particular attention, as there is a
fear that this will result in adverse drug reactions. The ma-
jority of publications about management of gout in CKD
included patients with a creatinine clearance >30 ml/min,
and there is little data on how to use ULTs in patients with
stage 4 CKD or maintained on dialysis [40]. Because of the
concern about adverse reactions, many patients with CKD
do not get to the therapeutic target level of urate with their
treatment, and some are not treated at all.
The ACR guidelines on the use of allopurinol in patients
with CKD differ from the information given in the manu-
facturer’s prescribing information and the dose adjustment
proposed by Hande [33]. The ACR guidelines recommend
starting allopurinol at a dose of 50 mg/day in stage 4 CKD;
the dosage can be raised gradually (by 50-mg increments)
to doses that may exceed 300 mg/day, but it is important
that this is accompanied by patient education and regular
monitoring.
For febuxostat there is no dose adjustment in mild-to-mod-
erate CKD. There is little data on its safety in stage 4 CKD
or in the dialysis setting [41]. Febuxostat 80 mg/day was
shown to more effective than 40 mg/day in achieving target
serum urate levels in cases of CKD with creatinine clear-
ance between 30 and 90 ml/min [42].
In the manufacturer’s prescribing information, probenecid
is not indicated in renal failure and in the ACR guidelines it
is not recommended as monotherapy in patients with a cre-
atinine clearance <50 ml/min.
The use of benzbromarone in CKD has been investigated
in only a limited number of studies. Perez-Ruiz concluded
that benzbromarone is more effective than allopurinol (the
dose of which was adjusted according to creatinine clear-
ance) in patients with moderate CKD (mean creatinine
clearance 54 ml/min) [43]. Benzbromarone in combination
with allopurinol had a significant effect of serum urate
level [40]. Finally, in a small Japanese study, patients with
CKD stage 3 or greater responded to benzbromarone
without worsening of renal function. These results are en-
couraging, but larger studies are required to confirm the
safety of benzbromarone in CKD.
For patients on haemodialysis, recommendations are
sparse. With allopurinol, prescription of 100 mg on altern-
ate days, given after dialysis, has been suggested. In the
case of daily dialysis, an additional 50% of the dose may
be required after dialysis [44]. In the American Index of
Drugs (Micromedex), it was reported that benzbromarone
is ineffective in patients on haemodialysis. For febuxostat
and probenecid there are no recommendations.
Discussion
The aim of this review was to bring together the latest in-
ternational recommendations on the management and treat-
ment of gout, and to provide the Swiss physician with an
update on what these guidelines recommend. The two arms
of gout therapy are (a) the relief of symptoms during an
acute attack, and (b) the reduction of urate levels to pre-
vent crystal formation and deposition. A common concept
of all recommendations is the need to treat to a specific
target urate level (treat-to-target) with the available range
of pharmacological agents, and to maintain urate levels be-
low this target in order to obtain remission. This target may
have to be adapted to the particular clinical situation (e.g.,
in tophaceous gout or patients who present frequent attacks
of polyarthritis) and requires thorough patient education
to ensure adherence. The need to give prophylaxis during
ULT is emphasised, as this will improve adherence to ULT,
which is usually life-long.
Although we have effective medications, their current
number is limited and we need to use the available drugs
correctly to achieve disease remission. One major problem
that is poorly covered in all the current guidelines is the
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choice of treatment in patients who have comorbid con-
ditions such as CKD, hypertension, diabetes or liver dis-
ease. These comorbidities are extremely common in the
gout population [45] and pose barriers to the use of partic-
ular drugs. A common problem is CKD, and there is cur-
rently insufficient data to recommend specific drugs that
are more effective or safer in this situation. However, both
for treating acute flares and for long term ULT therapy, the
physician has a number of alternatives, already mentioned
above, that may pose less of a risk to renal function and less
risk of drug side effects. Future research will need to fo-
cus more on this population to ensure that the recommend-
ations are based on solid evidence and not just expert opin-
ion.
In Switzerland, the physician treating gout faces an ad-
ditional challenge because of the limited availability of
drugs that are licensed and commonly used in neighbouring
countries. Colchicine is not included in the list of pharma-
ceutical specialities (Liste des Specialités Suisse), but is re-
cognised in the list of medications with tariff (Liste des
médicaments avec tarif). Febuxostat is not yet registered
in Switzerland, but is the only alternative xanthine oxidase
inhibitor for patients who do not tolerate allopurinol. Ben-
zbromarone was withdrawn from the Swiss market in 2003
and is not authorised by Swissmedic (the Swiss Agency for
Therapeutic Products), so its prescription is the entire re-
sponsibility of the prescribing physician. These examples
illustrate that treating gout is not always a simple affair in
Switzerland, and usually entails extra administrative work
in dealing with insurers.
Finally, for a disease that is so common, the available num-
ber of treatments is not great (two xanthine oxidase inhibit-
ors, two uricosurics). Hopefully, in the future, new medic-
ations will be discovered that will increase our therapeutic
armamentarium and provide alternatives to treat this very
curable disease.
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